|
|
Integrating Novel Therapies in Hemophilia in the Midst of Bridging Health Inequities
As the treatment armamentarium for patients with hemophilia continues to expand, there is an urgent need for healthcare providers to stay up-to-date on the latest advances so that they are prepared to integrate them into clinical practice. To bridge this gap, this interactive educational activity will provide a review of the science surrounding new and emerging hemophilia treatments and their mechanisms of action; recent safety and efficacy data from key clinical trials; and novel dosing strat... |
|
|
Practice-Changing Advances in the Management of Hemophilia
STATEMENT OF NEED
Hemophilia is an inherited bleeding disorder in which the blood does not clot properly, causing affected individuals to experience spontaneous bleeding as well as bleeding after injuries or surgery. The 2 most common types are hemophilia A, caused by low levels of clotting factor VIII; and hemophilia B, caused by low levels of clotting factor IX. The standard treatment for hemophilia involves replacing the missing blood clotting factor by infusing commercially prepared facto... |
|
|
Podcast: Practice-Changing Advances in the Management of Hemophilia
STATEMENT OF NEED
Hemophilia is an inherited bleeding disorder in which the blood does not clot properly, causing affected individuals to experience spontaneous bleeding as well as bleeding after injuries or surgery. The 2 most common types are hemophilia A, caused by low levels of clotting factor VIII; and hemophilia B, caused by low levels of clotting factor IX. The standard treatment for hemophilia involves replacing the missing blood clotting factor by infusing commercially prepared facto... |
|
|
Overcoming the Hurdles: Advances in the Management of Hemophilia
In this fast-moving, 1-hour accredited activity, Craig Kessler, MD, and Guy Young, MD, share their thoughts and experience with clotting factor concentrates, recombinant factor, factor VIII mimetics, rebalancing agents, and gene therapies. The safety and efficacy of late-phase investigational products are also discussed as these agents have the potential to address unmet needs and further transform patient care. |
|